Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a federal grant titled "Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research," aimed at establishing a consortium to enhance the identification, evaluation, validation, and harmonization of biomarkers critical for managing Type 1 Diabetes (T1D). The initiative seeks to address the urgent need for reliable and reproducible biomarkers by leveraging advanced methodologies in various scientific fields, ensuring that assays for established and newly identified biomarkers are rigorously validated across multiple laboratories. With an estimated total program funding of $5.2 million and the expectation of awarding approximately eight grants, interested applicants can reach out to the Division of Diabetes, Endocrinology and Metabolic Diseases at NIDDK_DEM@nih.gov for further information. The application process is set to begin with a synopsis posting on April 1, 2026, and will close on June 25, 2026, with awards anticipated by April 1, 2027.
Eligible Applicants
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).